Our research shows the transformative effect that alemtuzumab can have for people with MS.
Patients who continue to show disease activity while on their initial therapy are especially difficult to treat.
Now, we have shown that alemtuzumab works where first-line drugs have already failed.
It not only reduces the chances of disability associated with MS but may even result in long-term clinical improvements.
More top news
A shot of a chameleon using its tongue to grab dinner has snatched a top photography award.
One story dominates Thursday's front pages with some newspapers printing emotive pleas to voters to keep the United Kingdom as one.
After a mild start temperatures should pick up, with the south of England seeing highs of 26C.